1610 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphatic Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Unknown  Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Not yet recruiting Multicenter Phase II Study About the Combination of CHOP-21 With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma Patients.
Condition: Lymphatic Diseases
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib;   Drug: CHOP
4 Not yet recruiting Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Conditions: Hodgkin Disease;   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Neoplasms by Histologic Type
Intervention: Drug: ATLCAR.CD30 cells
5 Recruiting A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen
Condition: Lymphatic Diseases
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine
6 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
7 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
8 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
9 Not yet recruiting Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-05)
Condition: Relapsed, Diffuse Large B-cell Lymphoma
Intervention: Drug: Betalutin
10 Not yet recruiting Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: Betalutin with HH1 pre-dosing;   Drug: Betalutin with Rituximab pre-dosing
11 Recruiting Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular, Grade 3b;   Follicular Lymphoma, Grade 3b
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide
12 Recruiting Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
13 Recruiting Study Evaluating Venetoclax in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: venetoclax
14 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
15 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
16 Unknown  Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
17 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
18 Recruiting NIR Fluorescence Imaging of Lymphatic Transport Using ICG
Condition: Lymphedema
Interventions: Drug: Indocyanine Green;   Device: MultiSpectral Imaging System
19 Not yet recruiting The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
Condition: Lymphoma, B Cell
Intervention: Drug: KA2237
20 Recruiting Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Condition: Malignant Lymphoma
Intervention: Drug: PREBEN

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years